Perpetua Medical (PERP) Q1 2026 earnings summary

Executive summary

• Net sales increased by 54% year-over-year to 4,981 KSEK, mainly due to the acquisition of Spirotronic AB.

• Operating loss widened to -2,861 KSEK from -1,010 KSEK year-over-year, primarily due to higher costs and depreciation from acquisitions.

• Cash position at quarter-end was 20,284 KSEK, up from 7,213 KSEK a year earlier, supported by new share issues.

• No new acquisition agreements were signed during the quarter, but acquisition activity and pipeline development continued.

Financial highlights

• Earnings per share (EPS) was -0.33 SEK, compared to -0.28 SEK in the same quarter last year.

• Cash flow for the quarter was 15,951 KSEK, compared to -2,187 KSEK last year, mainly due to proceeds from share issues.

• Equity attributable to parent company shareholders was 18,249 KSEK, up from 6,565 KSEK year-over-year.

• Group equity ratio was 48%, down from 55% a year earlier.

Outlook and guidance

• Continued focus on acquiring profitable product companies in healthcare, with an expanded target list including larger companies.

• Management expects intensified news flow from subsidiaries in the second half of the year.

• Disciplined cost control and strong cash position provide time to execute acquisition strategy.